Physician profile
Henry N Ward
NPI 1811970130
$152,491.89
in general payments reported to CMS, 2019-2025
23 companies · $1,556 in 2025
The $1,556 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72K · 2020: $15K · 2021: $3,625 · 2022: $531 · 2023: $16K · 2024: $43K · 2025: $1,556.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $42K · Travel and Lodging: $15K · Food and Beverage: $4,830 · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $41,640.00 |
| Travel and Lodging | $14,764.27 |
| Food and Beverage | $4,829.88 |
| Education | $124.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $57,371.48 | 2023-2024 | Inpefa |
| Vifor Pharma, INC. | $28,883.41 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $19,435.95 | 2019-2025 | |
| Lundbeck LLC | $16,296.41 | 2019-2020 | |
| Amgen INC. | $15,779.49 | 2019-2023 | Repatha |
| Astrazeneca Pharmaceuticals Lp | $7,862.32 | 2019-2023 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $1,947.37 | 2021-2025 | |
| Medtronic Vascular, INC. | $1,509.55 | 2020 | |
| Novo Nordisk INC | $912.96 | 2021-2025 | Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $374.98 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $371.92 | 2021-2025 | Verquvo |
| Pfizer INC. | $277.40 | 2019-2021 | |
| Heartflow, INC. | $270.69 | 2023 | Ffrct |
| Portola Pharmaceuticals, LLC | $267.97 | 2019-2020 | |
| Lilly USA, LLC | $217.32 | 2023-2024 | Mounjaro |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $144.89 | 2022 | |
| Medtronic, INC. | $141.64 | 2023 | Ligasure |
| Janssen Pharmaceuticals, INC | $138.72 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $124.99 | 2023 | Amvuttra |
| Kiniksa Pharmaceuticals International, Plc | $101.17 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $23.55 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $23.16 | 2025 | Camzyos |
| Abbott Laboratories | $14.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.